DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED
Clinical trials for DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED trials appear
Sign up with your email to follow new studies for DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Race for a better treatment for devastating childhood brain cancer
Disease control Recruiting nowThis large, international Phase 3 trial aims to find a better treatment for diffuse intrinsic pontine glioma (DIPG), a rare and aggressive brain tumor with very few options. It will compare two drugs, ONC201 and everolimus, in over 430 patients, including children and adults, to …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Targeted drug trial offers hope for children with aggressive brain cancer
Disease control Recruiting nowThis study is testing a targeted drug called lorlatinib in children and young adults (ages 1-21) newly diagnosed with aggressive brain tumors (high-grade gliomas) that have specific genetic changes called ALK or ROS1 fusions. The main goals are to see if the drug can control the …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED
Phase: EARLY_PHASE1 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC